EYPT Strangle Strategy

EYPT (EyePoint Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.

EYPT (EyePoint Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.13B, a beta of 1.77 versus the broader market, a 52-week range of 5.35-19.11, average daily share volume of 1.3M, a public-listing history dating back to 2005, approximately 165 full-time employees. These structural characteristics shape how EYPT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.77 indicates EYPT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on EYPT?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current EYPT snapshot

As of May 15, 2026, spot at $12.46, ATM IV 69.60%, IV rank 8.17%, expected move 19.95%. The strangle on EYPT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on EYPT specifically: EYPT IV at 69.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a EYPT strangle, with a market-implied 1-standard-deviation move of approximately 19.95% (roughly $2.49 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EYPT expiries trade a higher absolute premium for lower per-day decay. Position sizing on EYPT should anchor to the underlying notional of $12.46 per share and to the trader's directional view on EYPT stock.

EYPT strangle setup

The EYPT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EYPT near $12.46, the first option leg uses a $13.08 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EYPT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EYPT shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$13.08N/A
Buy 1Put$11.84N/A

EYPT strangle risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

EYPT strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on EYPT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on EYPT

Strangles on EYPT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EYPT chain.

EYPT thesis for this strangle

The market-implied 1-standard-deviation range for EYPT extends from approximately $9.97 on the downside to $14.95 on the upside. A EYPT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current EYPT IV rank near 8.17% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on EYPT at 69.60%. As a Healthcare name, EYPT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EYPT-specific events.

EYPT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EYPT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EYPT alongside the broader basket even when EYPT-specific fundamentals are unchanged. Always rebuild the position from current EYPT chain quotes before placing a trade.

Frequently asked questions

What is a strangle on EYPT?
A strangle on EYPT is the strangle strategy applied to EYPT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With EYPT stock trading near $12.46, the strikes shown on this page are snapped to the nearest listed EYPT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are EYPT strangle max profit and max loss calculated?
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the EYPT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 69.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a EYPT strangle?
The breakeven for the EYPT strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EYPT market-implied 1-standard-deviation expected move is approximately 19.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on EYPT?
Strangles on EYPT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EYPT chain.
How does current EYPT implied volatility affect this strangle?
EYPT ATM IV is at 69.60% with IV rank near 8.17%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related EYPT analysis